We are monitoring the impact of COVID-19 on North America Multiple Sclerosis Drugs Market Get in touch with us for detailed analysis Know More
Pulished Date October, 2021
ID: 12223
Share on
Share on

North America Multiple Sclerosis drugs Market Research Report – Segmented By Drug class, Disease type, Route of administration, Distribution channel, and country (United States, Canada and Rest of North America) - Industry Analysis on Size, Share, Trends, COVID-19 Impact & Growth Forecast | 2021 to 2026

Pulished: October, 2021
ID: 12223
Pages: 100

North America Multiple Sclerosis  Market Size (2021 to 2026)

The North America multiple sclerosis drugs Market was worth USD 8.21 Billion in 2021 and is estimated to be growing at a CAGR of 6.81%, to reach USD 11.42 Billion by 2026.

Multiple sclerosis is a chronic, inflammatory, autoimmune disease that affects the central nervous system (CNS), particularly the communication between the brain and other areas of the body. 

The increasing incidence of multiple sclerosis and raising funding for multiple sclerosis research are the important driving factors in the expansion of the North American multiple sclerosis drugs markets.

Other factors such as increased funding, substantial research is being conducted on establishing novel drugs and therapies for multiple sclerosis, as well as various methods of finding potential causes of multiple sclerosis, are fuelling the market growth. 

Various organizations, such as the National Institute of Neurological Disorders and Stroke, the National MS Society, and the Parkinson’s Action Network, are working hard to develop new M.S. drugs which are propelling the market forward.

The prevalence of multiple sclerosis is rising at an alarming rate, posing a threat to healthcare professionals and the government. However, due to the disease’s increased prevalence, the government has been forced to take proactive actions in guidelines and recommendations.

 Aside from that, government organizations are launching numerous awareness campaigns to inform patients about the many treatment alternatives available, which is expected to positively impact market growth. For people with multiple sclerosis, the American Academy of Neurology (AAN) has developed a number of guidelines for initiating, switching, and stopping disease-modifying treatments.

On the other hand, several other factors, such as genetic and environmental factors, have a role in the higher prevalence of multiple sclerosis. Multiple sclerosis is also linked to autoimmune disorders such as Type 1 diabetes and certain infections, such as infectious mononucleosis. With the rising prevalence of this disease, demand for multiple sclerosis drugs is expected to rise in the future years, contributing to the market’s expansion. The rise in prevalence has increased demand for multiple sclerosis drugs, resulting in the expansion of the North America multiple sclerosis drugs market.

However, During the projection period, the high cost of the drugs used to treat multiple sclerosis would have a negative impact on the multiple sclerosis drugs market’s growth rates.

This research report on the North America multiple sclerosis drugs market has been segmented and sub-segmented into the following categories:

By Drug Class:

  • Interferon Beta
  • Sphingosine 1 Phosphate Receptor Modulators
  • Mixed Polymers
  • NF-κB Inhibitor
  • Pyrimidine Synthesis Inhibitor
  • Monoclonal Antibodies
  • Corticosteroids
  • Adrenocorticotropic Hormone
  • Others

By Disease Type:

  • Relapsing-remitting MS (RRMS)
  • Primary-progressive MS (PPMS)
  • Secondary-progressive MS (SPMS)
  • Progressive-relapsing MS (PRMS)

By Route of Administration:

  • Parenteral
  • Oral

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies & Drug Stores
  • Online Pharmacies

By Country:

  • United States
  • Canada
  • Rest of North America

The North America multiple sclerosis drugs market is valued at U.S. $ 13,900.7 million. The multiple sclerosis market is expected to substantially share due to rising drug costs and demand for multiple sclerosis therapy. Also, increased research and development spending, new product launches, and increasing demand for immunosuppressants contribute to the region’s dominant position in the multiple sclerosis drugs industry. In addition, the government in this region is aggressively pursuing measures to raise awareness about the M.S. treatment and diagnosis. As a result, in North America, the United States has the largest Multiple Sclerosis Drugs Market, followed by Canada.

The U.S. is anticipated to witness a significant share in the multiple sclerosis therapy market. Availability of advanced healthcare infrastructure, increasing healthcare spending, and favorable reimbursement policies are fueling the market growth. In addition, March is designated as Multiple Sclerosis Awareness Month in the United States, with educational programs supported by government organizations such as the Multiple Sclerosis Association of America. The multiple sclerosis treatment markets in North America are expected to be boosted as a result of this.

According to the Government of Canada, around 77,000 individuals in Canada were diagnosed with multiple sclerosis in 2014-2015. Furthermore, the Global Burden of Disease Study of 2016 found that North America had the highest age-standardized multiple sclerosis prevalence of 164.6 per 100,000 people. As a result, the increase in prevalence has resulted in a surge in demand for multiple sclerosis drugs in this region, supporting the market expansion.

KEY MARKET PLAYERS:

Bayer AG, Teva Pharmaceutical Industries Ltd., Novartis AG, Sanofi, F. Hoffmann-La Roche Ltd., Celgene Corporation, Acorda Therapeutics, Inc., Biogen, Inc., Actelion Pharmaceuticals (Johnson & Johnson), EMD Serono (Merck KGaA) and AbbVie, Inc. are a few of the promising companies operating in the North America multiple sclerosis drugs market.

1. Introduction                                   

            1.1 Market Definition            

            1.2 Scope of the report                     

            1.3 Study Assumptions                      

            1.4 Base Currency, Base Year and Forecast Periods             

2. Research Methodology                             

            2.1 Analysis Design                

            2.2 Research Phases              

                        2.2.1 Secondary Research     

                        2.2.2 Primary Research          

                        2.2.3 Data Modelling 

                        2.2.4 Expert Validation          

            2.3 Study Timeline                 

3. Report Overview                            

            3.1 Executive Summary                     

            3.2 Key Inferences                 

4. Market Dynamics                           

            4.1 Impact Analysis                

                        4.1.1 Drivers  

                        4.1.2 Restraints          

                        4.1.3 Opportunities   

            4.2 Regulatory Environment              

            4.3 Technology Timeline & Recent Trends                

5. Competitor Benchmarking Analysis                                  

            5.1 Key Player Benchmarking            

                        5.1.1 Market share analysis   

                        5.1.2 Products/Service          

                        5.1.3 Regional Presence        

            5.2 Mergers & Acquisition Landscape                       

            5.3 Joint Ventures & Collaborations              

6. Market Segmentation                                

            6.1 Multiple Sclerosis Drugs Market – By Drug Class:                       

                        6.1.1   Interferon Beta

                        6.1.2 Sphingosine 1 Phosphate Receptor Modulators          

                        6.1.3   Mixed Polymers          

                        6.1.4  NF-κB Inhibitor 

                        6.1.5  Pyrimidine Synthesis Inhibitor 

                        6.1.6  Monoclonal Antibodies

                        6.1.7 Corticosteroids 

                        6.1.8 Adrenocorticotropic Hormone 

                        6.1.9 Others   

                        6.1.10 Market Size Estimations & Forecasts (2021-2026)    

                        6.1.11 Y-o-Y Growth Rate Analysis    

                        6.1.12 Market Attractiveness Index  

            6.2 Multiple Sclerosis Drugs Market – By Disease Type:                  

                        6.2.1 Relapsing-remitting MS (RRMS)

                        6.2.2 Primary-progressive MS (PPMS)          

                        6.2.3 Secondary-progressive MS (SPMS)      

                        6.2.4    Progressive-relapsing MS (PRMS)      

                        6.2.5 Market Size Estimations & Forecasts (2021-2026)      

                        6.2.6 Y-o-Y Growth Rate Analysis      

                        6.2.7 Market Attractiveness Index    

            6.3 Multiple Sclerosis Drugs Market – By Route of Administration:             

                        6.3.1  Parenteral        

                        6.3.2   Oral     

                        6.3.3 Market Size Estimations & Forecasts (2021-2026)      

                        6.3.4 Y-o-Y Growth Rate Analysis      

                        6.3.5 Market Attractiveness Index    

            6.4 Multiple Sclerosis Drugs Market – By Distribution Channel:                  

                        6.4.1    Hospital Pharmacies  

                        6.4.2  Retail Pharmacies & Drug Stores         

                        6.4.3 Online Pharmacies        

                        6.4.4 Market Size Estimations & Forecasts (2021-2026)      

                        6.4.5 Y-o-Y Growth Rate Analysis      

                        6.4.6 Market Attractiveness Index    

7. Geographical Landscape                            

            7.1 North America - Market Analysis (2021 - 2026)              

                        7.1.1 By Country        

                                    7.1.1.1 USA

                                    7.1.1.2 Canada

                        7.1.2  By Drug Class:  

                        7.1.3 By Disease Type:           

                        7.1.4 By Route of Administration:     

                        7.1.5 By Distribution Channel:           

8. Key Player Analysis                        

            8.1 Bayer AG              

                        8.1.1 Business Description    

                        8.1.2 Products/Service          

                        8.1.3 Financials          

                        8.1.4 SWOT Analysis  

                        8.1.5 Recent Developments  

                        8.1.6 Analyst Overview          

            8.2 Teva Pharmaceutical Industries Ltd.                   

            8.3  Novartis AG                     

            8.4 Sanofi                   

            8.5  F. Hoffmann-La Roche Ltd.                     

            8.6 Celgene Corporation                   

            8.7 Acorda Therapeutics, Inc.            

            8.8 Biogen, Inc.                      

            8.9 Actelion Pharmaceuticals (Johnson & Johnson)             

            8.10 EMD Serono (Merck KGaA)                   

            8.11 AbbVie, Inc.                    

9. Market Outlook & Investment Opportunities                               

10. Appendix                          

            List of Tables              

            List of Figures             

  • Regional, and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and also identify the areas that are still untapped. 

  • The segment-level analysis in terms of drug class, disease type, route of administration, distribution channel and region along with market size forecasts and estimations to detect key areas of industry growth in detail.

  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics.

  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis.

  • Study the microenvironment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analyzing the level of competition and business strategy development.

  • A comprehensive list of key market players along with their product portfolio, current strategic interests, essential financial information, legal issues, SWOT analysis, and analyst overview to study and sustain the market environment.

  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies, and recent developments in the market by the major companies

  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis, and main conclusions.

  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations with a strong financial foothold in the market.

  1. North America multiple sclerosis drugs market By Drug Class, From 2021 to 2026 ( USD Billion )

  2. North America Interferon Beta Market By Region, From 2021 to 2026 ( USD Billion )

  3. North America Sphingosine 1 Phosphate Receptor Modulators Market By Region, From 2021 to 2026 ( USD Billion )

  4. North America   Mixed Polymers Market By Region, From 2021 to 2026 ( USD Billion )

  5. North America NF-κB Inhibitor Market By Region, From 2021 to 2026 ( USD Billion )

  6. North America Pyrimidine Synthesis Inhibitor Market By Region, From 2021 to 2026 ( USD Billion )

  7. North America Monoclonal Antibodies Market By Region, From 2021 to 2026 ( USD Billion )

  8. North America Corticosteroids Market By Region, From 2021 to 2026 ( USD Billion )

  9. North America Adrenocorticotropic Hormone Market By Region, From 2021 to 2026 ( USD Billion )

  10. North America  Others Market By Region, From 2021 to 2026 ( USD Billion )

  11. North America multiple sclerosis drugs market By Disease Type, From 2021 to 2026 ( USD Billion )

  12. North America Relapsing-remitting MS (RRMS) Market By Region, From 2021 to 2026 ( USD Billion )

  13. North America Primary-progressive MS (PPMS) Market By Region, From 2021 to 2026 ( USD Billion )

  14. North America  Secondary-progressive MS (SPMS) Market By Region, From 2021 to 2026 ( USD Billion )

  15. North America Progressive-relapsing MS (PRMS) Market By Region, From 2021 to 2026 ( USD Billion )

  16. North America multiple sclerosis drugs market By Route of Administration, From 2021 to 2026 ( USD Billion )

  17. North America Parenteral Market By Region, From 2021 to 2026 ( USD Billion )

  18. North America Oral Market By Region, From 2021 to 2026 ( USD Billion )

  19. North America multiple sclerosis drugs market By Distribution Channel, From 2021 to 2026 ( USD Billion )

  20. North America Hospital Pharmacies Market By Region, From 2021 to 2026 ( USD Billion )

  21. North America Retail Pharmacies & Drug Stores Market By Region, From 2021 to 2026 ( USD Billion )

  22. North America  Online Pharmacies Market By Region, From 2021 to 2026 ( USD Billion )

  23. United States multiple sclerosis drugs market By Drug Class, From 2021 to 2026 ( USD Billion )

  24. United States multiple sclerosis drugs market By Disease Type, From 2021 to 2026 ( USD Billion )

  25. United States multiple sclerosis drugs market By Route of Administration, From 2021 to 2026 ( USD Billion )

  26. United States multiple sclerosis drugs market By Distribution Channel, From 2021 to 2026 ( USD Billion )

  27. Canada multiple sclerosis drugs market By Drug Class, From 2021 to 2026 ( USD Billion )

  28. Canada multiple sclerosis drugs market By Disease Type, From 2021 to 2026 ( USD Billion )

  29. Canada multiple sclerosis drugs market By Route of Administration, From 2021 to 2026 ( USD Billion )

  30. Canada multiple sclerosis drugs market By Distribution Channel, From 2021 to 2026 ( USD Billion )

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample